Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methotrexate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR known ✓ | P00374 | 5/20 | 0.98 |
| ▸ | FPGS | Q05932 | 3/20 | 0.98 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.98 |
| ▸ | TLR4 | O00206 | 1/20 | 0.98 |
| ▸ | MEN1 | O00255 | 1/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.98 |
| ▸ | LMNA | P02545 | 1/20 | 0.98 |
| ▸ | TP53 | P04637 | 1/20 | 0.98 |
| ▸ | TYMS | P04818 | 1/20 | 0.98 |
| ▸ | GLA | P06280 | 1/20 | 0.98 |
| ▸ | POLB | P06746 | 1/20 | 0.98 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.98 |
| ▸ | MAPT | P10636 | 1/20 | 0.98 |
| ▸ | FOLR2 | P14207 | 1/20 | 0.98 |
| ▸ | FOLR1 | P15328 | 1/20 | 0.98 |
| ▸ | HPGD | P15428 | 1/20 | 0.98 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.98 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.98 |
| ▸ | GART | P22102 | 1/20 | 0.98 |
| ▸ | APEX1 | P27695 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methotrexate SCHEMBL1230258 | 1.00 | DHFR (0.98) | DHFRFPGSKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL30918997 | 1.00 | DHFR (0.98) | DHFRFPGSKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL31550530 | 1.00 | DHFR (0.98) | DHFRFPGSKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL23111684 | 1.00 | DHFR (0.98) | DHFRFPGSKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL5313424 | 1.00 | DHFR (0.98) | DHFRFPGSKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL23111685 | 1.00 | DHFR (0.98) | DHFRFPGSKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL11266991 | 1.00 | DHFR (0.98) | DHFRFPGSKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL31550529 | 1.00 | DHFR (0.98) | DHFRFPGSKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL11266999 | 1.00 | DHFR (0.98) | DHFRFPGSKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL171251 | 0.99 | DHFR (1.00) | DHFRFPGSKDM4ETLR4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119350340-A | Methotrexate hydrate crystal form DCI and preparation method and application thereof | 都创(上海)医药科技股份有限公司 | 2025-01-24 | — | — | CN | claimed |
| US-12023336-B2 | Antiviral drug compounds and composition thereof | NATIONAL CENTRE FOR CELL SCIENCE (IN) | 2024-07-02 | — | — | US | claimed |
| US-20200206231-A1 | TOPICAL PHARMACEUTICAL COMPOSITION, METHOD FOR PRODUCING THE TOPICAL PHARMACEUTICAL COMPOSITION, USE OF TOPICAL PHARMACEUTICAL COMPOSITION AND METHOD FOR TOPICAL TREATMENT OF PSORIASIS, ATOPIC DERMATITIS OR CHRONIC ECZEMA | BIOLAB SANUS FARMACEUTICA LTDA (BR) | 2020-07-02 | — | — | US | claimed |
| US-20190216815-A1 | COMBINATION THERAPY COMPRISING A POLYUNSATURATED KETONE AND A FOLIC ACID PARTNER | AVEXXIN AS (NO) | 2019-07-18 | — | — | US | claimed |
| EP-3463472-A1 | COMBINATION THERAPY COMPRISING A POLYUNSATURATED KETONE AND A FOLIC ACID PARTNER | Avexxin AS (NO) | 2019-04-10 | — | — | EP | claimed |
| EP-2839833-B1 | TOPICAL PHARMACEUTICAL COMPOSITION, METHOD FOR PRODUCING THE TOPICAL PHARMACEUTICAL COMPOSITION, USE OF THE TOPICAL PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TOPICAL TREATMENT OF PSORIASIS, ATOPIC DERMATITIS OR CHRONIC ECZEMA | BIOLAB SANUS FARMACEUTICA LTDA (BR) | 2018-06-13 | — | — | EP | claimed |
| WO-2017207820-A1 | COMBINATION THERAPY COMPRISING A POLYUNSATURATED KETONE AND A FOLIC ACID PARTNER | AVEXXIN AS (NO) | 2017-12-07 | — | — | WO | claimed |
| CN-1602841-A | Immuno-modulatory agents administration form for whole body or local immunity disorder | PEIJIN BIOTECHNOLOGY CO LTD (VG) | 2005-04-06 | — | — | CN | claimed |
| US-20040241217-A1 | Method for administration of immune modulators in systemic and localized immune disorders | PACGEN BIOPHARMACEUTICALS CORPORATION (CA) | 2004-12-02 | — | — | US | claimed |
| WO-2025264727-A1 | COMPOSITIONS AND METHODS OF SLC7A1 AND SLC7A2 | ARC RESEARCH INSTITUTE (US) | 2025-12-26 | — | — | WO | disclosed |
| US-20250290844-A1 | METHODS OF USING SHAPED PARTICLES IN FLOW CYTOMETERS FOR ASSAYS ON B CELLS AND T CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-09-18 | — | — | US | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| EP-3793561-B1 | METHOTREXATE COMPOUNDS FOR USE IN TREATING HIV INFECTIONS | NAT CENTRE FOR CELL SCIENCE (IN) | 2025-03-26 | — | — | EP | disclosed |
| US-12258360-B2 | Compositions and methods for treatment of anticancer-drug resistant cancers | THE GEORGE WASHINGTON UNIVERSITY (US) | 2025-03-25 | — | — | US | disclosed |
| US-20040241217-A1 | Method for administration of immune modulators in systemic and localized immune disorders | PACGEN BIOPHARMACEUTICALS CORPORATION (CA) | 2004-12-02 | — | — | US | disclosed |
| WO-2004031218-A1 | TUMOR TARGETING AGENTS AND USES THEREOF | KARYON OY (FI) | 2004-04-15 | — | — | WO | disclosed |
| WO-2004031220-A1 | TUMOR TARGETING AGENTS AND USES THEREOF | KARYON OY (FI) | 2004-04-15 | — | — | WO | disclosed |
| WO-2004031219-A1 | TUMOR TARGETING AGENTS AND USES THEREOF | KARYON OY (FI) | 2004-04-15 | — | — | WO | disclosed |
| EP-0836708-A1 | METHOD FOR ANTIBODY TO HEPATITIS C VIRUS SECOND ENVELOPE GLYCOPROTEIN | Abbott Laboratories (US) | 1998-04-22 | — | — | EP | disclosed |
| WO-1996041196-A1 | METHOD FOR DETECTION OF ANTIBODY TO HEPATITIS C VIRUS SECOND ENVELOPE GLYCOPROTEIN | ABBOTT LABORATORIES (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200206231-A1 | TOPICAL PHARMACEUTICAL COMPOSITION, METHOD FOR PRODUCING THE TOPICAL PHARMACEUTICAL COMPOSITION, USE OF TOPICAL PHARMACEUTICAL COMPOSITION AND METHOD FOR TOPICAL TREATMENT OF PSORIASIS, ATOPIC DERMATITIS OR CHRONIC ECZEMA | MTX1, MTX2, IL17A | DHFR 19/4885FPGS 495/4885KDM4E 2248/4885 |
| US-12258360-B2 | Compositions and methods for treatment of anticancer-drug resistant cancers | TP53, ANXA5, MCL1 | DHFR 128/4885FPGS 84/4885KDM4E 2165/4885 |
| US-20190216815-A1 | COMBINATION THERAPY COMPRISING A POLYUNSATURATED KETONE AND A FOLIC ACID PARTNER | FOLR2, MTHFD2, FOLR1 | DHFR 4/4885FPGS 11/4885KDM4E 2739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.